Work Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer ACT Biotech.

The total results presented at ASCO GI summarized the ongoing analysis of pharmacokinetic and pharmacodynamic data, focusing on the capability to dose telatinib in individuals with stomach cancer coupled with full-dose continuously, standard-of-care chemotherapy. In addition, morphological data from radiographic scans of tumor response demonstrated a distinctive and characteristic feature of powerful antiangiogenic activity from treatment with telatinib, verifying the on-target effect of the drug. Positive interim results of the Phase 2 trial of telatinib with combination chemotherapy for first-line treatment of metastatic abdomen cancer patients, a very difficult to treat population, in October 2010 and demonstrated fast onset of objective tumor responses in two-thirds of the treated patients were reported.Related StoriesCancer DNA in patient's bloodstream could help deliver personalized treatment for liver cancerUAB researcher awarded NIH grant to review pathogenesis of thrombotic microangiopathyCrucial transformation in single DNA bottom predisposes children to aggressive form of cancer’It’s such as a stack of copper pennies,’ said Barton. ‘And when in good condition and properly aligned, that stack of copper pennies can be conductive. But if those bases are mismatched or if there is any various other damage to the DNA, as can happen with damage that leads to cancer, the wire is interrupted and electricity shall not flow properly.’ Barton’s team founded that the electrons that comprise a stream of energy can move from one end of a DNA strand to the additional, just as they do through an electrical wire.